source
- Kyverna pauses development of next-gen autoimmune CAR-T KYV-102 to focus on neurologic miv-cel programKyverna Therapeutics announced it is halting work on its next-generation CD19 CAR-T candidate KYV-102, which had been positioned as a follow-up to its lead autoimmune CAR-T miv-cel. KYV-102 was de…
- Specialized AI tools could streamline medical device regulatory work, experts say, but need expert oversightAt a recent RAPS AI in Regulatory conference in Barcelona, a panel of experts discussed the role of specialized artificial intelligence in meeting regulatory requirements for medical devices. They…